NovaBay Pharmaceuticals (NYSE:NBY) Earns Hold Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of NovaBay Pharmaceuticals (NYSE:NBY) in a report published on Monday. The brokerage issued a hold rating on the stock.

NovaBay Pharmaceuticals Stock Up 2.3 %

Shares of NBY stock opened at $0.64 on Monday. The stock has a fifty day moving average of $0.66 and a 200 day moving average of $0.63. NovaBay Pharmaceuticals has a 52 week low of $0.36 and a 52 week high of $9.08. The firm has a market capitalization of $3.41 million, a price-to-earnings ratio of -0.01 and a beta of 0.73.

About NovaBay Pharmaceuticals

NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands.